Dianthus Therapeutics, Inc. DNTH R2KR3KPHARMA
Company Overview
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.11.
Recent Developments
- Dec 2025 Revenue of $2.04M (-67.3% YoY); net profit $-162.34M.
- Trailing 12 Months Year-on-year growth — revenue +294.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 294.30% |
Stock Price Performance
| 1 Year: | +418.47% |
| 6 Months: | +65.80% |
| 3 Months: | +34.27% |
| 1 Month: | -1.66% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)50.19 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | DNTH Dianthus Therapeutics, Inc. R2KR3KPHARMA | 108.10 | -25.50 | $5.91B | 0.00% | -35.57% | -26.06% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.17M | - | - | 924.00K | 874.00K | 1.86M | 2.17M | 1.16M | 193.00K | 396.00K | - | - |
| Operating Income | -4.81M | -15.73M | -7.01M | -8.17M | -11.31M | -14.03M | -16.70M | -17.93M | -16.35M | -19.34M | -22.64M | -24.64M | -21.24M | -20.01M | -18.38M | -18.70M | -17.61M | -18.25M | -23.83M | -18.08M | -8.25M | -7.68M | -11.78M | -15.76M | -17.84M | -22.20M | -29.90M | -33.18M | -34.93M | -40.29M | -46.53M | -61.48M |
| Net Income | -4.81M | -15.73M | -6.91M | -8.04M | -11.16M | -13.66M | -16.02M | -16.68M | -14.83M | -17.71M | -20.99M | -23.24M | -20.01M | -19.08M | -17.68M | -17.49M | -16.93M | -17.43M | -4.88M | -5.70M | -7.78M | -7.09M | -11.14M | -14.76M | -13.75M | -17.61M | -25.17M | -29.51M | -31.63M | -36.77M | -40.83M | -50.22M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.36 | -0.32 | -0.30 | -0.39 | -0.29 | -8.90 | -8.10 | -12.73 | -3.78 | -0.54 | -0.51 | -0.74 | -0.82 | -0.88 | -0.97 | -0.85 | -0.90 |
| R&D Expense | - | 13.82M | 5.21M | - | 7.85M | 9.68M | 11.42M | - | 10.54M | 13.43M | 16.52M | - | 13.96M | 12.61M | 11.79M | 11.73M | 11.13M | 10.79M | 16.55M | 11.60M | 7.22M | 5.85M | 10.25M | 7.96M | 13.08M | 18.07M | 25.54M | 27.00M | 26.25M | 32.49M | 34.53M | 48.69M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | - | - | - | 2.83M | 6.24M | 2.04M |
| Operating Income | -9.27M | -35.73M | -59.96M | -82.97M | -78.70M | -74.69M | -29.70M | -48.17M | -101.86M | -177.93M |
| Net Income | -9.43M | -35.49M | -57.52M | -76.77M | -74.94M | -71.14M | -28.48M | -43.55M | -84.97M | -162.34M |
| Diluted EPS | - | - | - | - | -1.71 | -1.29 | -32.57 | -8.45 | -2.55 | -4.20 |
| R&D Expense | 5.78M | 27.90M | 41.34M | 59.21M | 50.62M | 46.77M | 29.38M | 32.84M | 83.11M | 145.64M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 54.46M | 157.31M | 161.51M | 161.62M | 189.93M | 83.11M | 179.41M | 374.01M | 530.92M |
| Total Equity | -289.00K | -8.87M | -42.12M | 145.65M | 141.19M | 143.91M | -17.25M | -44.37M | 168.87M | 352.48M | 493.40M |
| Cash & Equivalents | - | - | 51.40M | 58.34M | 65.07M | 58.15M | 131.65M | 15.37M | 132.32M | 22.79M | 51.09M |
| Total Liabilities | - | - | 4.14M | 11.66M | 20.32M | 17.71M | 17.26M | 9.45M | 10.54M | 21.53M | 37.52M |
| Current Liabilities | - | - | 4.14M | 10.42M | 14.12M | 11.43M | 10.86M | 8.22M | 9.63M | 18.45M | 30.73M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -6.53M | -22.26M | -41.89M | -57.10M | -64.02M | - | -29.07M | -36.86M | -78.18M | -129.06M |
| Investing Cash Flow | -139.00K | -2.20M | -91.70M | 1.53M | -10.63M | - | -59.82M | 20.25M | -286.81M | -122.83M |
| Financing Cash Flow | 10.71M | 71.49M | 142.15M | 62.30M | 67.74M | - | 96.68M | 133.57M | 255.62M | 280.12M |
| Capital Expenditure | -139.00K | -2.20M | -7.67M | -3.06M | -400.00K | - | -139.00K | -110.00K | -105.00K | -213.00K |
| Free Cash Flow | -6.67M | -24.46M | -49.56M | -60.16M | -64.42M | - | -29.21M | -36.97M | -78.28M | -129.27M |
| Net Change in Cash | - | - | - | - | - | - | 7.79M | 116.97M | -109.37M | 28.23M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | -1,704.7% | -1,633.7% | -8,739.3% |
| Net Margin % | - | - | - | - | - | - | - | -1,541.2% | -1,362.8% | -7,973.3% |
| ROE % | 106.3% | 84.3% | -39.5% | -54.4% | -52.1% | 412.4% | 64.2% | -25.8% | -24.1% | -32.9% |
| ROCE % | - | -71.0% | -40.8% | -56.3% | -52.4% | -41.7% | -39.7% | -28.4% | -28.6% | -35.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 15.00% | 8.20M | $867.88M |
| 2 | Blackrock Inc. | 7.54% | 4.12M | $436.47M |
| 3 | T. Rowe Price Investment Management, Inc. | 7.11% | 3.89M | $411.55M |
| 4 | Wellington Management Group, LLP | 5.91% | 3.23M | $341.85M |
| 5 | Fairmount Funds Management LLC | 4.64% | 2.54M | $268.54M |
| 6 | Price (T.Rowe) Associates Inc | 4.60% | 2.51M | $266.18M |
| 7 | State Street Corporation | 4.31% | 2.36M | $249.51M |
| 8 | Vanguard Capital Management LLC | 3.95% | 2.16M | $228.57M |
| 9 | Avidity Partners Management, LP | 3.85% | 2.10M | $222.71M |
| 10 | Octagon Capital Advisors LP | 3.37% | 1.84M | $194.92M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for DNTH
Will Claseprubart’s Phase 3 Momentum and Parallel Autoimmune Trials Change Dianthus Therapeutics’ (DNTH) Narrative - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxQajBlcXRnVWZWRG0xV0xveWRpSWFxaWdBaUw4OFZnaEpmUWY4azlOOTUzdFZvUjd2WVI2R041dnRHVW40Y01fSjltaURXR20xUUVBcmRHVTBEYXJ3WlRmWE92Y3oxUVFSeGJiUDhQT1pySDlBTlBVbGlwNnZwVHlVd0NITWdxRWcxTktEUT…
Dianthus (DNTH) Piles Up Clinical Wins While Its Losses Widen - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPenpVLXNxTFBoWlhtOWtuMVB6dmpKdklMaGlBUERydmFvdlMybmlvdWFZTGJMU29yMExsN1JYaTZ1M2NxSDhjOS1iOEFPZGJwMEs3TkVBcnVWN1dBME9nN1NMWTIzR3Y0aHBnM29QLTd0U3JtWDJvTV9aNkY2a2JwRThKdDB3NU5IQ1NMdm…
Dianthus stock gains new Buy from Citi (DNTH:NASDAQ) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE9NLUotUDVKWFdUMmNfdy1OLVk2U0d0UnotYUg4TjltV0U2Z0ZyR281a3AtaU1fVGxvektJTXZVd1VjVkxwUGhtR1lsTzVOaTlOXzZNRnR6TFRQQzlmZGM5UFI4XzNXRlJrMTlkR2c0MjRBbmFjYXlsWDZ3SQ?oc=5" target="_blank">D…
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxNZkJ5em1kc1p3ZTB4ak96eWNaYWp2RWNKUWl6MzNBVGlZSl82Q0hCNndlVjJtN2V6LXRlQ3M2OGRDUUtIWFJVZDlvOUJzbVIyQ09TallLWUF0ODNuLTZJUXB5NVFLWFBEMFRpcmMyYWN4cFlXYzNrOUxQc3VfbVdXZWRmdkJkUVVfWWF1a1…
Officer at Dianthus (NASDAQ: DNTH) lines up 2026 stock sale after option exercise - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPSG96aVh3SVdzZHVZdDJTbmtFbndmc0lXZDdPeUxMVTBySG9UbHhxLUFpamFtRnJVbEUzYkJXVjFlRGFaUGRaUFptSGdLSk83VWJoaDE0eWhuNE0tZVQzd0Fmd1Y2QlNKaUZzSU9NT3JsU2VQTEtWS05Eamdpd2xLeExCbVNQWFRYUlhYck…
Discipline and Rules-Based Execution in DNTH Response - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNdEc1NFBtckNDMURjZkxVTHpaV1pYUlhXcnhWYkl1cXVhVDNnbGJNWFlRTkEwVDJrNEVIMm51Ymx5WnVhYXp5emtVOFF4TkcyME9wMzVnMTBac2NVWXRiVm95VHdOa0NNb1NTVEoya2Z5cTR1SmdrbVNUM3NfLW5jdUxtaldVa3N5Q09jMk…
DNTH — Frequently Asked Questions
What is the current share price of Dianthus Therapeutics, Inc. (DNTH)?
As of 2026-09-07 16:24 PDT, Dianthus Therapeutics, Inc. (DNTH) trades at $108.10 on NasdaqCM. Its 52-week range is $20.25 to $115.96.
What is the market capitalisation of DNTH?
Dianthus Therapeutics, Inc. (DNTH) has a market capitalisation of $5.91B on NasdaqCM.
What is the P/E ratio of DNTH?
DNTH trades at a trailing price-to-earnings (P/E) ratio of -25.50. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 5.09.
What is the return on equity (ROE) of DNTH?
DNTH has a return on equity (ROE) of -26.06%. Its return on capital employed (ROCE) is -35.57%.
Is DNTH a good stock to buy?
This page provides a data-driven analysis of Dianthus Therapeutics, Inc. (DNTH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.